News Feed

MPN News

MPN rss feedThe MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources.  Just click on the red hyperlink to pull up the complete news item.

Make PV Reporter your “starting point” for all MPN related news.


Gene expression-focused biotech Syros Pharmaceuticals, Inc. has snagged a collaboration deal with biopharma Incyte Corp. to develop potential therapeutics to treat rare bone marrow disorders known as myeloproliferative neoplasms (MPNs). In return for $20 million upfront in cash and R&D funding, and $10 million in stock, Syros will use its platform [...]
Thu, Jan 11, 2018, Continue reading at the source
By Ann Brazeau, CEO, MPN Advocacy and Education International In 2005, I met with the MPN Research Foundation for a potential job opportunity. Chairman Bob Rosen, Barbara Van Husen, President, and another Board member conducted the invigorating interview. The JAK2 Gene mutation had just been discovered and the energy and enthusiasm [...]
Thu, Jan 11, 2018, Continue reading at the source
MPN Research Foundation announced today with great sadness the passing of its Chairman and Founder, Robert Rosen, age 74. Diagnosed with polycythemia vera in 1997, Rosen was shocked to discover that little research was being conducted on his condition and that there were no advocacy groups working to assist people [...]
Tue, Jan 09, 2018, Continue reading at the source
Fedratinib is a highly selective JAK2 kinase inhibitor that is being evaluated for myelofibrosis and polycythemia vera Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naïve myelofibrosis patients and in a phase II trial with myelofibrosis patients resistant or intolerant to ruxolitinib A New Drug Application (NDA) submission for fedratinib [...]
Mon, Jan 08, 2018, Continue reading at the source
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies
Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in [...]
Sun, Jan 07, 2018, Continue reading at the source
Nutlin Antagonist Shows Activity in Polycythemia Vera
The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination [...]
Tue, Dec 26, 2017, Continue reading at the source
Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat [...]
Mon, Dec 18, 2017, Continue reading at the source
MPN clinical interests
One Simple Criteria If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and never published a peer reviewed research paper, he/she ain't likely to be an MPN specialist. Also, if their bio lists 10 – 12 clinical interests, [...]
Fri, Dec 01, 2017, Continue reading at the source
Pegasys Jakafi combo for MPNs
This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors and the use of ruxolitinib (RUX) in patients with myelofibrosis (MF) and patients [...]
Thu, Jun 29, 2017, Continue reading at the source
UT (University of Texas) San Antonio makes Dr. Ruben Mesa head of their Cancer Center Dr Ruben Mesa, one of the leading MPN Specialist in the world is accepting the role of the head of UT at San Antonio Cancer Center, where he will remain focused on MPN's. “Dr. Mesa's [...]
Thu, Jun 15, 2017, Continue reading at the source
For anyone who lives a fast-paced life, it is easy to sometimes forget our need to take care of ourselves and to listen to our bodies. It is easy to get distracted from the importance of a healthy lifestyle when it seems there is so much to be done. But it [...]
Tue, Mar 15, 2016, Continue reading at the source
February 29th is Rare Disease Day: 4 Reasons You Should Care Even though MPN patients who have a rare disease many may have never heard of "Rare Disease Day" and know next to nothing about the impact rare disorders have on society. Rare diseases play a larger role in public [...]
Mon, Feb 29, 2016, Continue reading at the source
It's World Cancer Day There has been, from time to time, a question about whether myeloproliferative neoplasms are cancers. Let's be clear, they are. But don't take our word for it. Cancer Support Community defines Myeloproliferative Neoplasms (MPNs) as types of blood cancers that overproduce blood cells in the bone [...]
Mon, Feb 01, 2016, Continue reading at the source
For the past several months we've kept you informed and taking action on Medicare's pending decision of whether to provide coverage for people with myelofibrosis seeking a stem cell transplant. Currently there is no official ruling from Medicare on whether this treatment is covered, leaving many patients to risk paying [...]
Tue, Jan 12, 2016, Continue reading at the source
Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We [...]
Sun, Dec 27, 2015, Continue reading at the source
According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, "This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in [...]
Tue, Dec 01, 2015, Continue reading at the source

Check out more resources at MPN Cancer Connection!Click here
error: Content is protected !!